These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 18712381)

  • 21. Metal-Chelating Polymers (MCPs) with Zwitterionic Pendant Groups Complexed to Trastuzumab Exhibit Decreased Liver Accumulation Compared to Polyanionic MCP Immunoconjugates.
    Liu P; Boyle AJ; Lu Y; Adams J; Chi Y; Reilly RM; Winnik MA
    Biomacromolecules; 2015 Nov; 16(11):3613-23. PubMed ID: 26469142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor uptake and tumor/blood ratios for [
    Al-Saden N; Cai Z; Reilly RM
    Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.
    Pastuskovas CV; Mundo EE; Williams SP; Nayak TK; Ho J; Ulufatu S; Clark S; Ross S; Cheng E; Parsons-Reponte K; Cain G; Van Hoy M; Majidy N; Bheddah S; dela Cruz Chuh J; Kozak KR; Lewin-Koh N; Nauka P; Bumbaca D; Sliwkowski M; Tibbitts J; Theil FP; Fielder PJ; Khawli LA; Boswell CA
    Mol Cancer Ther; 2012 Mar; 11(3):752-62. PubMed ID: 22222630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
    Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
    Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors.
    Hardee ME; Eapen RJ; Rabbani ZN; Dreher MR; Marks J; Blackwell KL; Dewhirst MW
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):219-28. PubMed ID: 18365198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy.
    Cornelissen B; Kersemans V; McLarty K; Tran L; Vallis KA; Reilly RM
    Nucl Med Biol; 2009 Oct; 36(7):811-9. PubMed ID: 19720293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.
    Le XF; Mao W; Lu C; Thornton A; Heymach JV; Sood AK; Bast RC
    Cell Cycle; 2008 Dec; 7(23):3747-58. PubMed ID: 19029832
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Kwon LY; Scollard DA; Reilly RM
    Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
    McKnight BN; Viola-Villegas NT
    Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT.
    Chan C; Scollard DA; McLarty K; Smith S; Reilly RM
    EJNMMI Res; 2011 Aug; 1(1):15. PubMed ID: 22214307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling.
    Nakanishi T; Chumsri S; Khakpour N; Brodie AH; Leyland-Jones B; Hamburger AW; Ross DD; Burger AM
    Br J Cancer; 2010 Mar; 102(5):815-26. PubMed ID: 20145614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
    Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
    J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
    Razumienko EJ; Scollard DA; Reilly RM
    J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.
    Heyerdahl H; Abbas N; Brevik EM; Mollatt C; Dahle J
    PLoS One; 2012; 7(8):e42345. PubMed ID: 22879947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
    Ritter CA; Perez-Torres M; Rinehart C; Guix M; Dugger T; Engelman JA; Arteaga CL
    Clin Cancer Res; 2007 Aug; 13(16):4909-19. PubMed ID: 17699871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts.
    Baker JH; Lindquist KE; Huxham LA; Kyle AH; Sy JT; Minchinton AI
    Clin Cancer Res; 2008 Apr; 14(7):2171-9. PubMed ID: 18381959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
    Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions.
    Hainfeld JF; O'Connor MJ; Dilmanian FA; Slatkin DN; Adams DJ; Smilowitz HM
    Br J Radiol; 2011 Jun; 84(1002):526-33. PubMed ID: 21081567
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Cai Z; Chattopadhyay N; Yang K; Kwon YL; Yook S; Pignol JP; Reilly RM
    Nucl Med Biol; 2016 Dec; 43(12):818-826. PubMed ID: 27788375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.